Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

Clinical Microbiology and Infection

Volumn 10, Issue 12, 2004, Pages 1062-1066

  Hsueh, P R ^a   Huang, L M ^a   Chen, P J ^a   Kao, C L ^b   Yang, P C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Coronavirus; IgA; IgG; IgM; Neutralisation antibody; SARS

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; RIBAVIRIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; PRIORITY JOURNAL; SEROCONVERSION; SEVERE ACUTE RESPIRATORY SYNDROME; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS STRAIN;

CORONAVIRUS; SARS ASSOCIATED CORONAVIRUS; SARS COV;

EID: 11044221237     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01009.x     Document Type: Article

References (16)

1. World Health Organization. Severe Acute Respiratory Syndrome (SARS): summary table of SARS cases by country, 1 November 2002 http://www.who.int/csr/sars/country/table2OO3_09_23/en/ (accessed 26 September 2003).
2. Hsueh PR, Hsiao CH, Yeh SH et al. Microbiologic characteristics, serologic response, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis 2003; 9: 1163-1167.
3. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953-1966.
4. Lee N, Hui D, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348 1986-1994.
5. Poutanen SM, Low DE, Henry B et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348: 1995-2005.
6. Tsang KW, Ho PL, Ooi GC et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1977-1985.
7. Wang JT, Sheng WH, Fang CT et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10: 818-824.
8. Hsueh PR, Chen PJ, Hsiao CH et al. Patient data, early SARS epidemic, Taiwan. Emerg Infect Dis 2004; 10: 489-493.
9. Hsueh PR, Yang PC. Severe acute respiratory syndrome (SARS)-an emerging infection of the 21st century. J Formos Med Assoc 2003; 102: 825-839.
10. Chang WT, Kao CL, Chung MY et al. SARS exposure and emergency department workers. Emerg Infect Dis 2004; 10: 1117-1119.
11. Huang LR, Chiu CM, Yeh SH et al. Evaluation of antibody responses against SARS coronavirus nucleocapsid or spike proteins by immunoblotting or ELISA. J Med Virol 2004; 73: 338-346.
12. Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967-1976.
13. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 2003; 349: 508-509.
14. Peiris JS, Chu CM, Cheng VC et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772.
15. Peiris JS, Lai ST, Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319-1325.
16. Wu HS, Chiu SC, Tseng TC et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis 2004; 9: 304-310.